Recombinant Human Interferon α-2b in the Treatment of Infants with Bronchiolitis by Different Routes of Administration

Yuan Yin; Peng Hua

doi:10.13407/j.cnki.jpp.1672-108X.2020.09.006

您当前的位置：

首页 >

文章列表页 >

Recombinant Human Interferon α-2b in the Treatment of Infants with Bronchiolitis by Different Routes of Administration

更新时间：2022-11-03

- Recombinant Human Interferon α-2b in the Treatment of Infants with Bronchiolitis by Different Routes of Administration
- Vol. 26, Issue 9, Pages: 19-22(2020)
- 作者机构：
  
  华中科技大学同济医学院附属协和医院,湖北,武汉,430022
- 作者简介：
- 基金信息：
- DOI：10.13407/j.cnki.jpp.1672-108X.2020.09.006
  CLC：
- Published：2020，
  
  Published Online：10 September 2020，
扫描看全文
Yuan Yin, Peng Hua. Recombinant Human Interferon α-2b in the Treatment of Infants with Bronchiolitis by Different Routes of Administration. [J]. 26(9):19-22(2020)
DOI：

Yuan Yin, Peng Hua. Recombinant Human Interferon α-2b in the Treatment of Infants with Bronchiolitis by Different Routes of Administration. [J]. 26(9):19-22(2020) DOI： 10.13407/j.cnki.jpp.1672-108X.2020.09.006.

摘要

目的：探讨重组人干扰素α-2b不同给药途径治疗婴幼儿毛细支气管炎的疗效及安全性。方法：回顾性分析我院2017年1月至2018年3月收治的符合纳入标准的毛细支气管炎患儿150例，采用随机数字表法分为对照组、雾化组和肌肉注射组各50例。三组患儿均给予常规治疗，雾化组加用雾化吸入重组人干扰素α-2b（每次100 000U/kg），肌肉注射组加用肌肉注射重组人干扰素α-2b（每次100 000U/kg-），比较两组患儿治疗前后血清白细胞介素-4（IL-4）、干扰素-γ（IFN-γ）水平，观察两组患儿临床疗效、临床症状体症消失时间及药物不良反应。结果：治疗后雾化组及肌肉注射组治疗总有效率高于对照组（P<0.05）；雾化组与肌肉注射组治疗总有效率比较差异无统计学意义（P>0.05）。随着时间的推移，三组患儿IL-4、IFN-γ均降低，差异均有统计学意义（P<0.05）；治疗前三组患儿IL-4、IFN-γ差异均无统计学意义（P>0.05），治疗后雾化组和肌肉注射组IL-4、IFN-γ水平均低于对照组（P<0.05），雾化组IL-4、IFN-γ水平低于肌肉注射组（P<0.05）。雾化组患儿总病程、咳嗽消失时间、干湿啰音消失时间、住院时间、喘息消失时间均较肌肉注射组缩短，差异有统计学意义（P<0.05）。雾化组患儿有1例食欲不振、1例肝功能受损及1例血小板减少；肌肉注射组有2例发热、3例食欲不振、1例肝功能受损、3例血小板减少及3例注射部位局部红斑；雾化组不良反应发生率低于肌肉注射组（P<0.05）。结论：重组干扰素α-2b治疗婴幼儿毛细支气管炎具有较好疗效，可有效改善患儿炎症因子水平，雾化吸入有利于缩短病程，较肌肉注射更加安全。

Abstract

Objective: To investigate the efficacy and safety of recombinant human interferon α-2b in the treatment of infants with bronchiolitis by different routes of administration. Methods: A total of 150 children with bronchiolitis admitted to our hospital from Jan. 2017 to Mar. 2018 were retrospectively extracted to be divided into the control group

atomization group and intramuscular injection group via the random number table

with 50 cases in each group. Three groups were given conventional treatment. Recombinant human interferon α-2b (100

000 U/kg) by ultrasonic atomizing inhalation was added to atomization group. Recombinant human interferon α-2b (100

000 U/kg) by intramuscular injection was added to intramuscular injection group. The levels of interleukin-4 (IL-4)

interferon-γ (IFN-γ) in the atomization group and intramuscular injection group were collected and analyzed before and after treatment. Clinical efficacy

disappearance time of clinical symptoms and adverse drug reactions of the atomization group and intramuscular injection group were observed. Results: After treatment

the total effective rate of the atomization group and the intramuscular injection group was higher than that of the control group (P<0.05)

the total effective rate of the atomization group and the intramuscular injection group was not statistically different (P>0.05). The levels of IL-4 and IFN-γ of three groups decreased after treatment

and the differences were statistically significant (P<0.05). There was no significant difference in IL-4 and IFN-γ in three groups before treatment (P>0.05). After treatment

the levels of IL-4 and IFN-γ in the atomization group and the intramuscular injection group were lower than those in the control group (P<0.05)

the levels of IL-4 and IFN-γ in the atomization group were lower than those in the intramuscular injection group (P<0.05). The total course of disease

the disappearance time of cough and lung rales

the length of stay

and the disappearance time of wheezing in the atomization group were all shorter than those in the intramuscular injection group

and the difference was statistically significant (P<0.05). In the atomization group

there were 1 case of loss of appetite

1 case of liver dysfunction

and 1 case of thrombocytopenia. While the intramuscular injection group had 2 cases of fever

3 cases of loss of appetite

1 case of liver dysfunction

3 cases of thrombocytopenia

and 3 cases of local erythema at the injection site. The incidence of adverse drug reactions in the atomization group was lower than that in the intramuscular injection group (P<0.05). Conclusion: Recombinant human interferon α-2b has significant curative effects in the treatment of infants with bronchiolitis and can effectively improve the level of inflammatory factors. Aerosol inhalation is beneficial to shorten the course of the disease and is safer than intramuscular injection.

关键词

重组干扰素α-2b毛细支气管炎给药途径婴幼儿

Keywords

recombinant interferon α-2bbronchiolitisroute of administrationnfants

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Characteristics of Neonatal Pertussis: Comparison with Infant Pertussis

Comparison of Efficacy of Budesonide and Salbutamol Aerosol Inhalation at Different Temperatures in Adjuvant Treatment of Children with Bronchiolitis

Effects of Antibiotics on Intestinal Flora in Infants of Mongolian and Han Nationality

Application of Budesonide Suspension for Inhalation in Pediatric Outpatient and Emergency Department of Our Hospital

Related Author

Zhong Qin

Feng Hui

Lu Qi

Wu Lunhui

Wei Yonggang

Liu Puxian

Xiao Daizhou

Wu Shuli

Related Institution

Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics

Chongqing Qianjiang Ethnic Hospital

Inner Mongolia People’s Hospital

Shenzhen Hospital of Integrated Chinese and Western Medicine

⁰